Acuta Capital Partners, LLC Adverum Biotechnologies, Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $18 Million - $37.8 Million	-1,746,500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $358,260 - $1.08 Million	42,000 Added 2.46%	1,746,500 $36.5 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $3.05 Million - $6.23 Million	382,000 Added 28.88%	1,704,500 $16.7 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $6.77 Million - $16.2 Million	1,322,500 New	1,322,500 $15.2 Million
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $6.24 Million - $18.9 Million	-1,190,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $1.38 Million - $3.22 Million	271,000 Added 29.49%	1,190,000 $14.1 Million
Q1 2019 May 14, 2019	BUY	$3.03 - $6.02 $2.78 Million - $5.53 Million	919,000 New	919,000 $4.82 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.